Skip to main content
SpringerLink
Log in

Macroprolactinemia, like hyperprolactinemia, may promote platelet activation

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

An Erratum to this article was published on 24 February 2010

Abstract

Insulin resistance, which provides a convenient milieu for platelet activation, has been closely associated with atherosclerotic disorders. Although it often accompanies hyperprolactinemia, findings conflict concerning its clinical impact in macroprolactinemia. In order to investigate the relationship between hyperprolactinemia and platelet activation evidenced by ADP-stimulated P-selectin expression on flow cytometry, we studied hyperprolactinemic, macroprolactinemic, and normoprolactinemic subjects. Thirty-four hyperprolactinemic and 44 age- and body mass index-matched euprolactinemic premenopausal women were included. They were matched regarding insulin sensitivity status, waist circumference, blood pressures, and plasma lipids. In order to detect macroprolactinemia among hyperprolactinemic cases, prolactin was measured before and after polyethylene glycol (PEG) precipitation in patients’ sera. P-selectin expression was significantly higher in the hyperprolactinemic group (P = 0.001), and 41.2% of them exhibited macroprolactinemia. Expression of P-selectin was comparable between the macroprolactin-negative (monomeric hyperprolactinemia; n = 20) and -positive (n = 14) subgroups (P = 0.90). Both subgroups showed greater expression compared with normoprolactinemic controls (P = 0.014 and 0.005, respectively). Platelet activation accompanies the atherosclerotic disorders closely associated with insulin resistance. Among groups matched with regard to insulin-sensitivity markers, both monomeric hyperprolactinemia and macroprolactinemia appeared to promote platelet activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. N. Ben-Jonathan, E.R. Hugo, T.D. Brandebourg, C.R. LaPensee, Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab. 17, 110–116 (2006)

    Article  CAS  PubMed  Google Scholar 

  2. R. Landgraf, M.M. Landraf-Leurs, A. Weissmann, R. Horl, K. von Werder, P.C. Scriba, Prolactin: a diabetogenic hormone. Diabetologia 13, 99–104 (1977)

    Article  CAS  PubMed  Google Scholar 

  3. M.C. Foss, F.J. Paula, G.M. Paccola, C.E. Piccinato, Peripheral glucose metabolism in human hyperprolactinemia. Clin. Endocrinol. 43, 721–726 (1995)

    Article  CAS  Google Scholar 

  4. A. Mavri, M.C. Alessi, I. Juhan-Vague, Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J. Intern. Med. 255, 448–456 (2004)

    Article  CAS  PubMed  Google Scholar 

  5. R.P. McEver, Leukocyte interactions mediated by P-selectin, in Structure, Function and Regulation of Molecules Involved in Leukocyte Adhesion, ed. by P.E. Lipsky, R. Rothlein, T.K. Kishimoto, R.B. Faanes, C.W. Smith (Springer Verlag, Edinburgh, 1991), pp. 135–150

    Google Scholar 

  6. K. Gokulakrishnan, R. Deepa, V. Mohan, D.M. Gross, Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study B. Metabolism 55, 237–242 (2006)

    Article  CAS  PubMed  Google Scholar 

  7. D. Tschoepe, E. Driesch, B. Schwippert, H.K. Nieuwenhuis, F.A. Gries, Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes 44, 890–894 (1995)

    Article  CAS  PubMed  Google Scholar 

  8. H. Koyama, T. Maeno, S. Fukumoto, T. Shoji, T. Yamane, H. Yokoyama, M. Emoto, T. Shoji, H. Tahara, M. Inaba, M. Hino, A. Shioi, T. Miki, Y. Nishizawa, Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108, 524–529 (2003)

    Article  CAS  PubMed  Google Scholar 

  9. S. Nomura, M. Suzuki, K. Katsura, G.L. Xie, Y. Miyazaki, T. Miyake, H. Kido, H. Kagawa, S. Fukuhara, Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116, 235–240 (1995)

    Article  CAS  PubMed  Google Scholar 

  10. H. Wallaschofski, M. Donné, M. Eigenthaler, B. Hentschel, R. Faber, H. Stepan, M. Koksch, T. Lohmann, PRL as novel potent cofactor for platelet aggregation. J. Clin. Endocrinol. Metab. 86, 5912–5919 (2001)

    Article  CAS  PubMed  Google Scholar 

  11. H. Wallaschofski, A. Kobsar, M. Koksch, A. Siegemund, B. Hentschel, U. Tuschy, T. Lohmann, O. Sokolova, M. Eigenthaler, Prolactin receptor signaling during platelet activation. Horm. Metab. Res. 35, 228–235 (2003)

    Article  CAS  PubMed  Google Scholar 

  12. M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000)

    CAS  PubMed  Google Scholar 

  13. J. Gibney, T.P. Smith, T.J. McKenna, Clinical relevance of macroprolactin. Clin. Endocrinol. 62, 633–643 (2005)

    Article  CAS  Google Scholar 

  14. H. Sadideen, R. Swaminathan, Macroprolactin: what is it and what is its importance? Int. J. Clin. Pract. 60, 457–461 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, HOMA; Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)

    Article  CAS  PubMed  Google Scholar 

  16. International Diabetes Federation. IDF consensus worldwide definition of the metabolic syndrome (2005), http://www.idf.org/metabolic_syndrome. Accessed 10 Dec 2009

  17. A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)

    Article  CAS  PubMed  Google Scholar 

  18. H. Wallaschofski, T. Lohmann, E. Hild, A. Kobsar, A. Siegemund, E. Spilcke-Liss, B. Hentschel, C. Stumpf, W.G. Daniel, C.D. Garlichs, M. Eigenthaler, Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb. Haemost. 96, 38–44 (2006)

    CAS  PubMed  Google Scholar 

  19. D. Raaz, H. Wallaschofski, C. Stumpf, A. Yılmaz, I. Cicha, L. Klinghammer, W.G. Daniel, T. Lohmann, C.D. Garlichs, Increased prolactin in acute coronary syndromes as putative co-activator of ADP stimulated P-selectin expression. Horm. Metab. Res. 38, 67–72 (2006)

    Article  Google Scholar 

  20. A.Q. Reuwer, R. Nieuwland, I. Fernandez, V. Goffin, C.M. van Tiel, M.C. Schaaap, R.J. Berckmans, J.J. Kastelein, M.T. Twickler, Prolactin does not affect human platelet aggregation or secretion. Thromb. Haemost. 101, 119–1127 (2009)

    Google Scholar 

  21. M. Merten, P. Thiagarajan, P-selectin in arterial thrombosis. Z. Kardiol. 93, 855–863 (2004)

    Article  CAS  PubMed  Google Scholar 

  22. A.D. Blann, S.K. Kadar, G.Y. Lip, The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 24, 2166–2179 (2003)

    Article  CAS  PubMed  Google Scholar 

  23. V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. 37, 365–372 (1992)

    Article  CAS  Google Scholar 

  24. N. Hattori, C. Inagaki, Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J. Clin. Endocrinol. Metabol. 82, 3107–3110 (1997)

    Article  CAS  Google Scholar 

  25. H.E. Carlson, E. Markoff, D.W. Lee, On the nature of serum prolactin in two patients with macroprolactinemia. Fertil. Steril. 58, 78–87 (1992)

    CAS  PubMed  Google Scholar 

  26. M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)

    CAS  PubMed  Google Scholar 

  27. O.M. Hauache, A.J. Rocha, A.C. Maia, R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. 57, 327–331 (2002)

    Article  CAS  Google Scholar 

  28. K.S. Vallette, R.I. Morange, A. Selim, G. Gunz, S. Morange, A. Enjalbert, P.M. Martin, P. Jaquet, T. Brue, Macroprolactinemia revisited: a study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)

    Article  Google Scholar 

  29. C. Mounier, J. Trouillas, B. Claustrat, R. Duthel, B. Estour, Macroprolactinaemia associated with prolactin adenoma. Hum. Reprod. 18, 853–857 (2003)

    Article  CAS  PubMed  Google Scholar 

  30. A.O. Olukoga, T.L. Dornan, J.W. Kane, Three cases of macroprolactinaemia. J. R. Soc. Med. 92, 342–344 (1999)

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mr. Oktay Sozer for flow cytometric platelet analysis, and also Dr. Tarik Zafer Nursal for assistance with statistical analyses.

Disclosures

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Baskent University Faculty of Medicine, Ankara, Turkey

    Inan Anaforoglu, Melek Eda Ertorer, Filiz Eksi Haydardedeoglu, Okan Bakiner, Emre Bozkirli, Neslihan Bascil Tutuncu & Nilgun Guvener Demirag

  2. Department of Hematology, University Faculty of Medicine, Ankara, Turkey

    Ilknur Kozanoglu

  3. Department of Biochemistry, Baskent University Faculty of Medicine, Ankara, Turkey

    Birsel Unal

  4. Tıp Fakültesi İstanbul Hastanesi, Başkent Üniversitesi, Oymacı Sokak No: 7, Altunizade, 34662, Istanbul, Turkey

    Nilgun Guvener Demirag

Authors
  1. Inan Anaforoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melek Eda Ertorer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilknur Kozanoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Birsel Unal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Filiz Eksi Haydardedeoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Okan Bakiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emre Bozkirli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neslihan Bascil Tutuncu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nilgun Guvener Demirag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilgun Guvener Demirag.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s12020-010-9309-5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anaforoglu, I., Ertorer, M.E., Kozanoglu, I. et al. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocr 37, 294–300 (2010). https://doi.org/10.1007/s12020-009-9304-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-009-9304-x

Keywords

Search

Navigation